Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Iovance Biotherapeutics Inc (IOVA)

Iovance Biotherapeutics Inc (IOVA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,520,140
  • Shares Outstanding, K 411,962
  • Annual Sales, $ 263,500 K
  • Annual Income, $ -390,980 K
  • EBIT $ -367 M
  • EBITDA $ -327 M
  • 60-Month Beta 0.69
  • Price/Sales 6.05
  • Price/Cash Flow N/A
  • Price/Book 2.20

Options Overview Details

View History
  • Implied Volatility 222.58% (+114.63%)
  • Historical Volatility 115.14%
  • IV Percentile 72%
  • IV Rank 15.26%
  • IV High 1,223.10% on 07/21/25
  • IV Low 42.44% on 06/25/25
  • Expected Move (DTE 5) 0.28 (7.60%)
  • Put/Call Vol Ratio 0.08
  • Today's Volume 6,920
  • Volume Avg (30-Day) 14,168
  • Put/Call OI Ratio 0.31
  • Today's Open Interest 208,416
  • Open Int (30-Day) 182,623
  • Expected Range 3.41 to 3.97

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 13 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate -0.17
  • Number of Estimates 3
  • High Estimate -0.15
  • Low Estimate -0.21
  • Prior Year -0.36
  • Growth Rate Est. (year over year) +52.78%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.81 +31.32%
on 02/23/26
5.63 -34.46%
on 03/09/26
+0.82 (+28.57%)
since 02/20/26
3-Month
2.21 +66.97%
on 01/15/26
5.63 -34.46%
on 03/09/26
+1.21 (+48.79%)
since 12/19/25
52-Week
1.64 +125.21%
on 05/19/25
5.63 -34.46%
on 03/09/26
+0.15 (+4.24%)
since 03/20/25

Most Recent Stories

More News
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

SAN CARLOS, Calif., March 20, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and delivering...

IOVA : 3.69 (-4.65%)
Why 2 Small Biotechs May Hold the Key to New Cancer Treatments

Iovance and ImmunityBio have doubled and quadrupled in share price so far this year, respectively, thanks to powerful cancer medicines that could upend care.

IOVA : 3.69 (-4.65%)
IBRX : 8.47 (-3.97%)
Iovance Biotherapeutics to Present at Upcoming Conferences

SAN CARLOS, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating...

IOVA : 3.69 (-4.65%)
Iovance Biotherapeutics: Q4 Earnings Snapshot

Iovance Biotherapeutics: Q4 Earnings Snapshot

IOVA : 3.69 (-4.65%)
Iovance Biotherapeutics Highlights Strong Fourth Quarter and Full Year 2025 Results, Business Achievements and Corporate Updates

~30% Quarterly Revenue Growth Driven by Amtagvi Demand Gross Margin Increased to 50% FY25 Revenue of $264M Achieved Annual Guidance U.S. FDA Fast Track Designation Granted for Lifileucel...

IOVA : 3.69 (-4.65%)
Iovance Announces Positive Results from the First Clinical Trial for TIL Cell Therapy in Soft Tissue Sarcomas

50% Objective Response Rate (ORR) in Advanced Sarcomas Significant Market Opportunity with More than 8,000 Patients Diagnosed Annually in the U.S. and Europe SAN CARLOS, Calif., Feb. 24, 2026...

IOVA : 3.69 (-4.65%)
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

SAN CARLOS, Calif., Feb. 20, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and delivering...

IOVA : 3.69 (-4.65%)
Iovance Biotherapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Corporate Updates on Tuesday, February 24, 2026

SAN CARLOS, Calif., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating...

IOVA : 3.69 (-4.65%)
Best-in-Class Real-World Data Support Early Amtagvi® Treatment in Advanced Melanoma

SAN CARLOS, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal...

IOVA : 3.69 (-4.65%)
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

SAN CARLOS, Calif., Jan. 16, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and delivering...

IOVA : 3.69 (-4.65%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

Relative Strength just crossed below 50%. The market is indicating support for a bearish trend.

See More Share

Business Summary

Iovance Biotherapeutics is a clinical-stage pharmaceutical company primarily focused on the development and commercialization of novel T cell-based cancer immunotherapies. These immunotherapies use Generation 2 ('Gen 2') tumor infiltrating lymphocyte (TIL), which harnesses the power of a patient's own...

See More

Key Turning Points

3rd Resistance Point 4.24
2nd Resistance Point 4.10
1st Resistance Point 3.89
Last Price 3.69
1st Support Level 3.55
2nd Support Level 3.41
3rd Support Level 3.20

See More

52-Week High 5.63
Fibonacci 61.8% 4.11
Last Price 3.69
Fibonacci 50% 3.63
Fibonacci 38.2% 3.16
52-Week Low 1.64

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.